The management of high-risk biochemically recurrent (BCR) prostate cancer—a condition characterized by rising prostate-specific antigen (PSA) levels following definitive primary treatment—has reached a significant clinical inflection point. As revealed in the third installment of the Future Oncology podcast series, investigators from the landmark Phase III EMBARK trial (NCT02319837) have synthesized years of data to provide a clearer roadmap for clinicians navigating this complex therapeutic landscape.
The EMBARK study, which served as the foundation for recent regulatory approvals by the FDA and EMA, has demonstrated that the use of enzalutamide, either in combination with leuprolide or as a monotherapy, significantly improves outcomes compared to traditional androgen deprivation therapy (ADT) alone. This article synthesizes the key clinical findings, the evolving role of imaging, and the practical implications for oncologists and urologists worldwide.
Main Facts: The Shift in Treatment Paradigms
The primary objective of the EMBARK trial was to evaluate the efficacy of androgen receptor pathway inhibitors (ARPIs) in patients with non-metastatic, high-risk BCR prostate cancer—a group previously often relegated to watchful waiting or delayed systemic intervention.
Dr. Stephen Freedland, a urologist at Cedars-Sinai Medical Center, and Dr. Ugo De Giorgi, a clinical oncologist at the University of Salento, underscore that the trial’s primary endpoint, metastasis-free survival (MFS), was met with statistically significant and clinically meaningful improvements across treatment arms. Crucially, the long-term follow-up data from EMBARK have revealed a dramatic improvement in overall survival for patients receiving the combination of enzalutamide plus leuprolide.
While the monotherapy arm showed numerical improvements in overall survival compared to ADT, it did not reach the threshold for statistical significance. However, the trial successfully demonstrated that these treatment pathways do not compromise patient quality of life, effectively dispelling fears that more aggressive systemic intervention would come at the cost of daily patient wellbeing.
Chronology of the EMBARK Evidence
The trajectory of the EMBARK trial reflects the broader evolution of prostate cancer management:
- Trial Initiation and Design: The study was designed to enroll patients with high-risk BCR, defined by a PSA doubling time of 9 months or less, post-definitive surgery or radiation therapy. Conventional imaging (CT and bone scan) was used at the outset to ensure patients were classified as non-metastatic.
- Primary Efficacy Data: Early results established that both enzalutamide combination therapy and monotherapy outperformed ADT alone in delaying the progression to metastatic disease or death.
- Subsequent Analyses: Subsequent post hoc analyses delved deeper into specific subgroups, assessing the impact of age, the type of prior definitive therapy (surgery vs. radiation), and adherence to European Association of Urology (EAU) high-risk criteria.
- Long-Term Follow-up: The most recent data highlighted the significant overall survival advantage of the combination therapy, cementing its role as a potential standard of care.
- Integration of Modern Imaging: The dialogue has now shifted to the role of PSMA-PET (Prostate-Specific Membrane Antigen Positron Emission Tomography) in refining patient selection, as the trial’s initial definition of "non-metastatic" was based on conventional imaging—an area that requires modern interpretation.
Supporting Data: Efficacy Across Subgroups
The clinical strength of the EMBARK findings lies in their consistency across diverse patient profiles. Dr. De Giorgi noted that the benefits of enzalutamide—with or without leuprolide—were observed regardless of whether a patient had undergone prior radical prostatectomy, radiation therapy, or a combination of both.
Efficacy Endpoints and PSA Dynamics
A key metric of success in the trial was the ability of patients to achieve undetectable PSA levels (defined as <0.2 ng/mL). Patients treated with the combination or monotherapy were significantly more likely to reach this milestone. An essential finding, with profound implications for clinical practice, was that those who achieved undetectable PSA levels after treatment re-initiation exhibited longer MFS. This suggests that PSA monitoring remains a vital tool for dynamic, ongoing risk assessment.
Age and Safety Profiles
While serious adverse events (SAEs) were more common in patients aged 70 and older, the incidence of treatment-related SAEs remained relatively low across all age groups. This data provides reassurance to clinicians that age alone should not be an absolute contraindication for systemic ARPI therapy.
Quality of Life and Sexual Health
One of the most nuanced areas of the EMBARK findings is the patient-reported outcome (PRO) data. Because enzalutamide monotherapy allows for the preservation of testosterone levels, the trial observed that sexual activity, interest in sex, and overall satisfaction with sexual life were better preserved in the monotherapy group compared to those receiving leuprolide-based combinations. This distinction is paramount for patients who prioritize sexual health during their treatment course.
Official Responses and Clinical Implications
The transition from clinical trial data to bedside practice requires a nuanced approach, particularly regarding the incorporation of PSMA-PET imaging and the selection between monotherapy and combination therapy.
The Role of Imaging
Dr. Freedland addressed the "burning question" of how to layer PSMA-PET on top of the EMBARK findings. With up to 84% of EMBARK-like patients showing PSMA-positive disease in recent studies, the traditional definition of "non-metastatic" is being challenged. Clinicians are now urged to use a risk-stratified approach. For patients with high-risk BCR who test negative on conventional imaging but may have oligometastatic disease on PSMA-PET, a multidisciplinary approach—combining systemic therapy with metastasis-directed therapy (MDT)—is increasingly viewed as the standard of excellence.
Shared Decision-Making
The decision to initiate therapy requires an honest dialogue about the patient’s goals. If a patient is highly motivated to maintain sexual function, monotherapy may be a viable, albeit complex, choice. However, clinicians must be prepared to manage the specific side effects associated with monotherapy, such as gynecomastia and breast tenderness.
Dr. De Giorgi emphasized that in the absence of specific trial data on prophylaxis, many practitioners are now utilizing established strategies from the bicalutamide experience, such as prophylactic breast irradiation or the use of tamoxifen. These interventions, when implemented before the start of treatment, can significantly improve the patient experience.
The Future of High-Risk BCR Management
The EMBARK investigators conclude that we are entering an era of precision in BCR management. The "one-size-fits-all" approach is being replaced by a model that considers:
- Biological Risk: Using PSA doubling time and genomic classifiers to identify the highest-risk patients.
- Imaging Precision: Utilizing PSMA-PET to detect early oligometastatic disease that might otherwise go untreated.
- Personalized Tolerance: Selecting therapy based on the patient’s desire to balance systemic control with quality-of-life factors like sexual health and hormonal symptom management.
The publication of these findings in Future Oncology serves as a critical resource for the oncology community. By moving beyond the initial headline-grabbing MFS and overall survival data, the subsequent analyses of the EMBARK trial provide the granular detail necessary for doctors to provide truly personalized care.
As Dr. Freedland concluded in the podcast, the goal remains clear: "We are starting to see this evidence build that combining the two—systemic therapy and targeted intervention—really can give dramatic improvement for our patients." For those in the high-risk BCR population, this represents a significant step forward in shifting a diagnosis of biochemical recurrence from a period of uncertainty to a manageable, treatable, and increasingly survivable condition.
Disclosures: The podcast and subsequent analysis discussed in this article were funded by Pfizer and Astellas. The authors, Dr. Stephen J. Freedland and Dr. Ugo De Giorgi, have disclosed relevant financial relationships with multiple pharmaceutical entities, including Pfizer and Astellas, and adhere to strict ethical guidelines regarding the integrity of the data presented. For full disclosure details, please refer to the original publication in Future Oncology.
About the Author
